Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Betterlife Pharma Inc (OP: BETRF )

0.0756 UNCHANGED
Streaming Delayed Price Updated: 1:01 PM EDT, Aug 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0756
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0756
Today's Range 0.0756 - 0.0756
52wk Range 0.0309 - 0.1500
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BetterLife Announces Closing of a Private Placement
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife Announces Closing of a Private Placement
From BetterLife Pharma Inc.
Via GlobeNewswire

Performance

YTD
+30.12%
+30.12%
1 Month
-27.24%
-27.24%
3 Month
-13.60%
-13.60%
6 Month
+18.68%
+18.68%
1 Year
+29.67%
+29.67%

More News

Read More
BetterLife To Present BETR-001 Preclinical Data at the 2024 Conference of the Federation of European Neuroscience Societies (FENS) in Vienna, Austria
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife Announces Intent to Complete Private Placement of Units
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife Advances BETR-001 IND-enabling Studies
From BetterLife Pharma Inc.
Via GlobeNewswire
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Via Benzinga
BetterLife To Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
From BetterLife Pharma Inc.
Via GlobeNewswire
Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
Via Benzinga
BetterLife Announces Closing of $1.168 Million Convertible Debentures to Further Advance IND-enabling Studies of its Non-hallucinogenic LSD-based Drug Candidate BETR-001
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife’s 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife Announces Closing of a Private Placement
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife Announces Extension of Warrants
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife Pharma to Host Investors Update Call on September 18, 2023
From BetterLife Pharma Inc.
Via GlobeNewswire
US Patent and Trademark Office Publishes BetterLife’s Comprehensive Patent for BETR-001 and Other LSD Derivatives
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife Highlights BETR-001 Article in Technology Networks Drug Discovery and Announces Closing of a Private Placement
From BetterLife Pharma Inc.
Via GlobeNewswire
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
Via Benzinga
BetterLife Highlights American College of Physicians’ Updated Guidelines for Treating Depression and Announces Closing of Private Placement
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife Fast Tracks Its US Patent For Non-Hallucinogenic Compound And Other LSD Derivatives
Via Benzinga
BetterLife Fast Tracks Its US Patent for BETR-001 and Other LSD Derivatives
From BetterLife Pharma Inc.
Via GlobeNewswire
BetterLife To Present BETR-001 Preclinical Data at the 32nd Annual Meeting of the International Behavioural Neuroscience Society (IBNS) in Niagara Falls, Ontario, Canada
From BetterLife Pharma Inc.
Via GlobeNewswire
Psyched: Dubai Psychedelics Event, Key Receptor Discovered, Drew Barrymore, Oprah's Guest, Swiss MDMA & More
Via Benzinga
BetterLife's Non-Hallucinogenic LSD's Clinical Studies, Braxia's Psychedelic Treatments Continue
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.